177 related articles for article (PubMed ID: 21194431)
21. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience.
Mazzanti R; Arena U; Pantaleo P; Antonuzzo L; Cipriani G; Neri B; Giordano C; Lanini F; Marchetti S; Gentilini P
Can J Gastroenterol; 2004 Oct; 18(10):611-8. PubMed ID: 15497001
[TBL] [Abstract][Full Text] [Related]
22. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
[TBL] [Abstract][Full Text] [Related]
23. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma.
Gao F; Gu YK; Fan WJ; Zhang L; Huang JH
World J Gastroenterol; 2011 Jul; 17(26):3145-50. PubMed ID: 21912458
[TBL] [Abstract][Full Text] [Related]
25. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
Liu G; Ouyang Q; Xia F; Fan G; Yu J; Zhang C; Wang D
HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783
[TBL] [Abstract][Full Text] [Related]
26. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
27. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
28. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
[TBL] [Abstract][Full Text] [Related]
29. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
[TBL] [Abstract][Full Text] [Related]
30. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
[TBL] [Abstract][Full Text] [Related]
31. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
32. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
[TBL] [Abstract][Full Text] [Related]
33. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
[TBL] [Abstract][Full Text] [Related]
34. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact.
Lee YH; Hsu CY; Huang YH; Hsia CY; Chiou YY; Su CW; Lin HC; Huo TI
J Clin Gastroenterol; 2014 Sep; 48(8):734-41. PubMed ID: 24100755
[TBL] [Abstract][Full Text] [Related]
35. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies.
Nouso K; Matsumoto E; Kobayashi Y; Nakamura S; Tanaka H; Osawa T; Ikeda H; Araki Y; Sakaguchi K; Shiratori Y
J Gastroenterol Hepatol; 2008 Mar; 23(3):453-8. PubMed ID: 17725599
[TBL] [Abstract][Full Text] [Related]
37. Predictors of long-term survival in hepatocellular carcinomas: A longitudinal follow-up of 108 patients with small tumors.
Chang HC; Lin YM; Yen AM; Chen SL; Wu WY; Chiu SY; Fann JC; Lin YS; Chen HH; Liao CS
Anticancer Res; 2013 Nov; 33(11):5171-8. PubMed ID: 24222166
[TBL] [Abstract][Full Text] [Related]
38. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Huang YH; Lee PC; Chang FY; Lee SD
Liver Transpl; 2004 Dec; 10(12):1507-13. PubMed ID: 15558587
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients.
Xu HX; Lu MD; Xie XY; Yin XY; Kuang M; Chen JW; Xu ZF; Liu GJ
Clin Radiol; 2005 Sep; 60(9):1018-25. PubMed ID: 16124984
[TBL] [Abstract][Full Text] [Related]
40. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
Kitai S; Kudo M; Izumi N; Kaneko S; Ku Y; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Kadoya M; Matsuyama Y; Matsunaga T
Dig Dis; 2014; 32(6):717-24. PubMed ID: 25376289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
